BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tunlucabtagene autoleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tunlucabtagene autoleucel\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06153251-3271@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20300502
DTEND;VALUE=DATE:20300503
SUMMARY:Tunlucabtagene autoleucel: Phase 1 readout est. (NCT06153251)
DESCRIPTION:Tunlucabtagene autoleucel\, phase 1\, Multiple Myeloma.\nStudy:
  A Study to Assess BMS-986453 in Participants With Relapsed and/or Refract
 ory Multiple Myeloma\nEstimated primary completion: 2 May 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tunlucabtagene-autoleucel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06153251
URL:https://assetmemo.bio/drug/tunlucabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07333261-3271@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tunlucabtagene autoleucel: Phase 1 readout est. (NCT07333261)
DESCRIPTION:Tunlucabtagene autoleucel\, phase 1\, Multiple Myeloma.\nStudy:
  Study of BMS-986453 in Newly Diagnosed Multiple Myeloma\nEstimated primar
 y completion: December 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tunlucabtagene-autoleucel#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07333261
URL:https://assetmemo.bio/drug/tunlucabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
